imPROve-asthma - A prospective, 24-month, observational study to investigate the change in Patient-Reported Outcomes in severe eosinophilic asthma patients treated with benralizumab biologic therapy under real-life conditions in Germany
18 Years - n/a
Endpoint Classification: -
Intervention Model: -
Primary Purpose: -
Verified 01 Nov 2023 by AstraZeneca
No locations available
|Primary Study Cohort - Anti-IL5/IL5R naïve patients|
Severe eosinophilic asthma patients who have never received anti-Interleukin-5 / anti-Interleukin-5-receptor (anti-IL-5/anti-IL-5R) biologic treatment for severe eosinophilic asthma, for whom the investigator had decided to initiate benralizumab biologic treatment.
|Secondary Study Cohort - Biologic experienced patients|
Patients that previously received a biologic treatment for severe asthma (at least one dose).